Mechanistically, FGFR blockade suppresses CAF proliferation and migration, as well as the release of vascular cell adhesion molecule 1 (VCAM-1) via MAPK/ERK pathway downregulation in CAFs, disrupting both physical and chemical barriers in the tumor immune microenvironment (TIME) [72]. Here, VCAM1 is linked to neoplasm.